An angina drug dating back to the 1970s until its use was curtailed due to toxicity is back in development, this time aimed at rare hereditary heart disease hypertrophic cardiomyopathy (HCM) in the hands of Heart Metabolics Ltd., which relaunched as an Irish firm and disclosed Thursday a $20 million series A round.